Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Nathan SD, et al. Among authors: shen e. Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. Lancet Respir Med. 2021. PMID: 34214475 Clinical Trial.
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
Nathan SD, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, Shen E, Deng C, Smith P, Waxman A. Nathan SD, et al. Among authors: shen e. Am J Respir Crit Care Med. 2022 Jan 15;205(2):198-207. doi: 10.1164/rccm.202107-1766OC. Am J Respir Crit Care Med. 2022. PMID: 34767495 Free PMC article.
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.
Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Nikkho SM, et al. Among authors: shen e. Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. eCollection 2022 Jul. Pulm Circ. 2022. PMID: 36016668 Free PMC article. Review.
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, Feldman J, Hajari Case A, Argula RG, Tapson V, Smith P, Deng C, Shen E, Nathan SD. Waxman A, et al. Among authors: shen e. Eur Respir J. 2023 Jun 29;61(6):2202414. doi: 10.1183/13993003.02414-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37080567 Free PMC article. Clinical Trial.
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.
Miller CE, Franco V, Smith JS, Balasubramanian V, Kingrey J, Zolty R, Melendres-Groves L, Huston J, Elwing JM, Ravichandran A, Cella D, Shen E, Seaman S, Thrasher CM, Broderick M, Oudiz RJ. Miller CE, et al. Among authors: shen e. Respir Med. 2023 Nov;218:107374. doi: 10.1016/j.rmed.2023.107374. Epub 2023 Aug 1. Respir Med. 2023. PMID: 37532157 Free article.
715 results